Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15427005 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15427002 | 0.90 | LMNA (0.54) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15427014 | 0.89 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL19270406 | 0.88 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15426992 | 0.88 | MAPT (0.74) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15426998 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15426986 | 0.85 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15427062 | 0.85 | LMNA (0.62) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15426995 | 0.84 | MAPT (0.78) | SMN1; SMN2ALDH1A1GAAHTTTSHR | |
| SCHEMBL15427079 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1GAAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596646-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596646-B2 | Oligonucleotide compositions and methods thereof | SMN1; SMN2, RBM17, RBM22 | SMN1; SMN2 1/4885ALDH1A1 2965/4885GAA 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.